Pembrolizumab autoimmune related diabetes: Moving forward, keep learning

Area of Science:

• Oncology
• Immunology
• Endocrinology

Background:

• Immune checkpoint inhibitors (ICIs), particularly programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors such as Pembrolizumab, have transformed melanoma treatment and are expanding to other cancers.
• ICIs are used in various clinical settings, including adjuvant and neoadjuvant therapy for potentially curable cancers, improving patient survival.
• Endocrinological adverse events are common side effects of ICI therapy.

Discussion:

• Pembrolizumab-induced type 1 diabetes mellitus (T1DM) is a rare but severe complication of ICI therapy.
• This ICI-induced T1DM can lead to significant morbidity and mortality, with long-term impacts on quality of life.
• The exact mechanisms driving Pembrolizumab-induced T1DM require further investigation.

Key Insights:

• Pembrolizumab can induce type 1 diabetes, a serious and potentially irreversible side effect.
• This condition presents with distinct clinical features and carries a high risk of complications.
• Understanding the etiopathogenesis is vital for managing patients at risk.

Outlook:

• Further research into the mechanisms of ICI-induced T1DM is necessary.
• Multidisciplinary collaboration between oncologists and endocrinologists is essential for patient management.
• Developing strategies for early detection and intervention in patients receiving ICIs is a priority.